Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash from Financing Activities (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Cash from Financing Activities for 7 consecutive years, with $705.2 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 25405.21% to $705.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $990.7 million through Dec 2025, up 62.72% year-over-year, with the annual reading at $990.7 million for FY2025, 62.72% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $705.2 million at Kymera Therapeutics, up from $39.5 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $705.2 million in Q4 2025, with the low at -$206000.0 in Q3 2023.
  • Average Cash from Financing Activities over 5 years is $100.4 million, with a median of $1.9 million recorded in 2022.
  • The sharpest move saw Cash from Financing Activities tumbled 100.14% in 2023, then surged 121904.85% in 2024.
  • Over 5 years, Cash from Financing Activities stood at $2.1 million in 2021, then fell by 4.92% to $2.0 million in 2022, then dropped by 0.97% to $1.9 million in 2023, then skyrocketed by 42.97% to $2.8 million in 2024, then skyrocketed by 25405.21% to $705.2 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $705.2 million, $39.5 million, and $245.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.